How Medications Affect Orthodontic Treatment in the UK

Why medications matter in orthodontics

Orthodontic treatment relies on a precisely controlled biological process: the periodontal ligament and surrounding alveolar bone must remodel in response to carefully applied mechanical forces. Dozens of commonly prescribed medications interfere with this process at various points — some affect the gum tissue, others alter bone turnover, and others reduce saliva flow or immune defences. In the UK, where many adults take one or more long-term prescription medicines, medication disclosure at consultation is not a formality — it is a clinical necessity. Your orthodontist is trained to recognise drug interactions with treatment and to modify the plan, seek GP advice, or refer to a specialist when needed. Never omit any medication from your health history form, including supplements, herbal remedies, and over-the-counter drugs.

Calcium channel blockers and gingival hyperplasia

Calcium channel blockers — including amlodipine, nifedipine, diltiazem, and verapamil — are widely prescribed in the UK for hypertension and angina. A well-documented side effect is drug-induced gingival overgrowth (also called gingival hyperplasia), occurring in approximately 10–20% of users. The gum tissue enlarges, particularly in the papillae between teeth, creating a thickened, sometimes nodular appearance. This overgrown tissue is harder to keep clean, traps plaque around brackets, and can obscure the bracket base — making bonding and force delivery less predictable. It also increases the risk of pseudo-pocketing and secondary periodontal inflammation. Before starting orthodontics, the prescribing doctor should be consulted about switching to an alternative antihypertensive that does not carry this side effect. If switching is not possible, a periodontal assessment and professional cleaning programme should be established before brace fitting, and hygiene support continued throughout treatment.

Phenytoin and marked gingival overgrowth

Phenytoin (Epanutin) is an older anticonvulsant used to manage epilepsy. It produces gingival overgrowth in approximately 50% of users — a significantly higher rate than calcium channel blockers. The overgrowth is most pronounced in the anterior (front) gum areas and can be severe enough to partially cover the tooth crowns, making orthodontic bracket placement very difficult. Poor oral hygiene dramatically worsens the severity. For patients taking phenytoin who require orthodontics, a periodontal assessment and thorough cleaning are mandatory before treatment begins. Surgical gingivectomy or laser crown lengthening may be needed to expose sufficient tooth surface for bonding. Referral to a specialist orthodontist is advisable in moderate to severe cases. Liaison with the neurologist about alternative anticonvulsant options may be appropriate, though medication changes for epilepsy must be managed very carefully and must not be undertaken without specialist input.

Bisphosphonates and risks for orthodontic tooth movement

Bisphosphonates — including alendronic acid (widely prescribed in the UK for osteoporosis), risedronate, ibandronate, and zoledronic acid — work by inhibiting osteoclast activity and reducing bone resorption. This is beneficial for preserving skeletal bone density, but it has significant implications for orthodontics. Tooth movement depends on a cycle of bone resorption (by osteoclasts) and deposition (by osteoblasts). By suppressing osteoclast function, bisphosphonates slow or impair this remodelling cycle, resulting in slower and less predictable tooth movement. In some cases, teeth may barely move at all. There is also a risk of medication-related osteonecrosis of the jaw (MRONJ) — a serious complication where jaw bone fails to heal following a wound such as an extraction. MRONJ risk is higher with intravenous bisphosphonates (used in cancer treatment) than with oral bisphosphonates, but the risk is non-zero even with low-dose oral use over several years. Any planned orthodontic extractions in bisphosphonate users must be discussed carefully, and an oral and maxillofacial surgery opinion may be warranted. The duration of prior bisphosphonate use and any history of dental healing problems should be documented.

SSRIs, antidepressants, and the bone density paradox

Selective serotonin reuptake inhibitors (SSRIs) — including fluoxetine, sertraline, citalopram, and escitalopram — are among the most commonly prescribed drugs in the UK. Their relationship with orthodontics is complex. On one hand, SSRIs have been associated in some research with reduced bone mineral density and impaired osseointegration, which could theoretically slow tooth movement. On the other hand, some studies suggest that serotonin receptors in bone cells may actually promote bone formation under certain conditions. The clinical significance in routine orthodontics is uncertain. More practically relevant is the dry mouth (xerostomia) that many SSRIs and tricyclic antidepressants cause: reduced saliva flow impairs the natural buffering and remineralisation of tooth enamel, increasing cavity risk — particularly relevant for clear aligner wearers who may sip drinks while wearing aligners. Patients taking antidepressants should be particularly diligent about fluoride use and hygiene.

Corticosteroids and bone metabolism

Long-term systemic corticosteroids (such as prednisolone, used for autoimmune conditions, severe asthma, or inflammatory bowel disease) suppress inflammation and immune function, and also affect bone metabolism. Prolonged corticosteroid use is associated with reduced bone density and suppressed osteoblast activity. These effects can slow bone remodelling during orthodontic treatment and may prolong treatment duration. Patients taking corticosteroids also have a degree of immune suppression, which can impair resistance to periodontal infection and delay healing. The orthodontist should be aware of the underlying condition being treated, the dose and duration of steroid use, and any associated dental complications. Inhaled corticosteroids for asthma carry much lower systemic absorption and generally pose a lower risk, though rinsing the mouth after use is advisable to prevent oral candidiasis.

Anticoagulants and bleeding on adjustment

Patients taking anticoagulants — including warfarin, rivaroxaban, apixaban, edoxaban, or clopidogrel — should inform their orthodontist before treatment begins. These drugs do not typically prevent orthodontic treatment but require management consideration. Gum bleeding can be more pronounced and prolonged after routine orthodontic adjustments when anticoagulant therapy is active. More significant is the risk around any planned extractions: orthodontic extractions in anticoagulated patients must be coordinated with the prescribing doctor. For warfarin users, INR checks before extraction are standard practice. Newer direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban generally do not require bridging therapy for minor procedures, but specialist guidance should be followed. Local haemostatic measures such as resorbable packing and suturing are routinely employed.

ADHD medications and xerostomia

Stimulant medications used for ADHD — including methylphenidate (Ritalin, Concerta) and lisdexamfetamine (Vyvanse) — commonly cause dry mouth as a side effect. Reduced saliva flow significantly increases the risk of dental decay, white spot lesions around brackets, and gum inflammation during orthodontic treatment. Patients taking these medications need to be particularly vigilant about oral hygiene, use high-fluoride toothpaste (1,450 ppm or higher), stay well hydrated, and consider fluoride varnish applications at each orthodontic review. This is particularly important in teenage patients, who may already have irregular brushing habits. Orthodontists and patients' dentists should work together to monitor enamel health closely throughout treatment.

What to disclose at your orthodontic consultation

You should disclose all current and recent medications at your orthodontic consultation, including prescription medicines, over-the-counter drugs (such as aspirin or ibuprofen taken regularly), supplements (vitamin D, calcium, fish oil), herbal remedies, and any injectables or infusions. Do not assume a medication is irrelevant — your orthodontist will make that assessment. You should also disclose any planned medication changes, upcoming surgical procedures, or recent changes in medical condition. Bring a current NHS prescription or a list prepared by your GP if you take multiple medications. In complex cases, your orthodontist may write to your GP or specialist to discuss the implications for treatment.

Medication reviews with your GP before starting

For certain medications — particularly bisphosphonates, phenytoin, and calcium channel blockers — it is worth requesting a medication review with your GP before orthodontic treatment begins. In many cases, an equivalent drug without the relevant dental side effects can be prescribed. For example, amlodipine can sometimes be substituted with an ACE inhibitor or ARB for blood pressure management. For phenytoin, many patients have already been transitioned to newer anticonvulsants, but those who have not may benefit from a review. Your orthodontist can write a supporting letter explaining the clinical reason for the review. Changes to epilepsy medication or anticoagulation should never be made without specialist oversight.

Useful related pages

This guide is for general information only. It is not a diagnosis, treatment plan, or substitute for advice from a registered dentist or orthodontist.